159 related articles for article (PubMed ID: 26218173)
1. Paediatric obesity: can medications help.
Lenders CM
Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):331-9. PubMed ID: 26218173
[TBL] [Abstract][Full Text] [Related]
2. Is there a path for approval of an antiobesity drug: what did the Sibutramine Cardiovascular Outcomes Trial find?
Downey M; Still C; Sharma AM
Curr Opin Endocrinol Diabetes Obes; 2011 Oct; 18(5):321-7. PubMed ID: 21878755
[TBL] [Abstract][Full Text] [Related]
3. Obesity medications: what does the future look like?
Butsch WS
Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):360-6. PubMed ID: 26313898
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy in pediatric obesity: current evidence and landscape.
Singhal V; Sella AC; Malhotra S
Curr Opin Endocrinol Diabetes Obes; 2021 Feb; 28(1):55-63. PubMed ID: 33186194
[TBL] [Abstract][Full Text] [Related]
5. Companies throw their weight behind new antiobesity drugs.
Cahoon L
Nat Med; 2010 Feb; 16(2):136. PubMed ID: 20134442
[No Abstract] [Full Text] [Related]
6. Pharmacotherapy in the Management of Pediatric Obesity.
Kelly AS; Fox CK
Curr Diab Rep; 2017 Aug; 17(8):55. PubMed ID: 28646356
[TBL] [Abstract][Full Text] [Related]
7. New treatment modalities for obesity.
Grandone A; Di Sessa A; Umano GR; Toraldo R; Miraglia Del Giudice E
Best Pract Res Clin Endocrinol Metab; 2018 Aug; 32(4):535-549. PubMed ID: 30086873
[TBL] [Abstract][Full Text] [Related]
8. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders.
Heal DJ; Gosden J; Smith SL
Br J Clin Pharmacol; 2009 Dec; 68(6):861-74. PubMed ID: 20002080
[TBL] [Abstract][Full Text] [Related]
9. [Drug treatment of obesity--current situation and perspectives].
Hainer V
Cas Lek Cesk; 2010; 149(11):513-9. PubMed ID: 21391349
[TBL] [Abstract][Full Text] [Related]
10. The development of pharmacological treatment of obesity in children. A European regulatory perspective.
Karres J; Tomasi P; Saint Raymond A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 May; 54(5):570-6. PubMed ID: 21547648
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines.
Correia ML; Haynes WG
Expert Opin Emerg Drugs; 2005 Aug; 10(3):643-60. PubMed ID: 16083333
[TBL] [Abstract][Full Text] [Related]
12. Pediatric obesity pharmacotherapy: current state of the field, review of the literature and clinical trial considerations.
Kelly AS; Fox CK; Rudser KD; Gross AC; Ryder JR
Int J Obes (Lond); 2016 Jul; 40(7):1043-50. PubMed ID: 27113643
[TBL] [Abstract][Full Text] [Related]
13. Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s.
Thomas CE; Mauer EA; Shukla AP; Rathi S; Aronne LJ
Obesity (Silver Spring); 2016 Sep; 24(9):1955-61. PubMed ID: 27569120
[TBL] [Abstract][Full Text] [Related]
14. Drug treatment of obesity in the cardiovascular patient.
Charakida M; Tousoulis D; Finer N
Curr Opin Cardiol; 2013 Sep; 28(5):584-91. PubMed ID: 23928924
[TBL] [Abstract][Full Text] [Related]
15. Current and future pharmacotherapies for obesity in children and adolescents.
Kelly AS
Nat Rev Endocrinol; 2023 Sep; 19(9):534-541. PubMed ID: 37337008
[TBL] [Abstract][Full Text] [Related]
16. Trends in prescribing anti-obesity pharmacotherapy for paediatric weight management: Data from the POWER Work Group.
Borzutzky C; King E; Fox CK; Stratbucker W; Tucker J; Yee JK; Kumar S; Cuda S; Sweeney B; Kirk S; On Behalf Of The Power Work Group
Pediatr Obes; 2021 Jan; 16(1):e12701. PubMed ID: 32877010
[TBL] [Abstract][Full Text] [Related]
17. New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.
Taylor JR; Dietrich E; Powell JG
Clin Ther; 2013 Jan; 35(1):A3-17. PubMed ID: 23328274
[TBL] [Abstract][Full Text] [Related]
18. Update on Pediatric Anti-obesity Medications-Current Landscape and Approach to Prescribing.
Ahn YJ; Maya J; Singhal V
Curr Obes Rep; 2024 Jun; 13(2):295-312. PubMed ID: 38689134
[TBL] [Abstract][Full Text] [Related]
19. New drug targets for the treatment of obesity.
Powell AG; Apovian CM; Aronne LJ
Clin Pharmacol Ther; 2011 Jul; 90(1):40-51. PubMed ID: 21654742
[TBL] [Abstract][Full Text] [Related]
20. Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies.
Jackson VM; Price DA; Carpino PA
Expert Opin Investig Drugs; 2014 Aug; 23(8):1055-66. PubMed ID: 25000213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
